Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Catherine F, Slattery"'
Autor:
Jenny Hällqvist, Rui C. Pinto, Wendy E. Heywood, Jonjo Cordey, Alexander J. M. Foulkes, Catherine F. Slattery, Claire A. Leckey, Eimear C. Murphy, Henrik Zetterberg, Jonathan M. Schott, Kevin Mills, Ross W. Paterson
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 18, p 13758 (2023)
As disease-modifying therapies are now available for Alzheimer’s disease (AD), accessible, accurate and affordable biomarkers to support diagnosis are urgently needed. We sought to develop a mass spectrometry-based urine test as a high-throughput s
Externí odkaz:
https://doaj.org/article/e9943eb950d94943b26b11c8409c7684
Autor:
Mirthe Coenen, Geert Jan Biessels, Charles DeCarli, Evan F. Fletcher, Pauline M. Maillard, Frederik Barkhof, Josephine Barnes, Thomas Benke, Jooske M.F. Boomsma, Christopher P.L.H. Chen, Peter Dal-Bianco, Anna Dewenter, Marco Duering, Christian Enzinger, Michael Ewers, Lieza G. Exalto, Nicolai Franzmeier, Onno Groeneveld, Saima Hilal, Edith Hofer, Huiberdina L. Koek, Andrea B. Maier, Cheryl R. McCreary, Janne M. Papma, Ross W. Paterson, Yolande A.L. Pijnenburg, Anna Rubinski, Reinhold Schmidt, Jonathan M. Schott, Catherine F. Slattery, Eric E. Smith, Carole H. Sudre, Rebecca M.E. Steketee, Esther van den Berg, Wiesje M. van der Flier, Narayanaswamy Venketasubramanian, Meike W. Vernooij, Frank J. Wolters, Xu Xin, J. Matthijs Biesbroek, Hugo J. Kuijf
Publikováno v:
NeuroImage: Clinical, Vol 40, Iss , Pp 103547- (2023)
Introduction: The spatial distribution of white matter hyperintensities (WMH) on MRI is often considered in the diagnostic evaluation of patients with cognitive problems. In some patients, clinicians may classify WMH patterns as “unusual”, but th
Externí odkaz:
https://doaj.org/article/5540ab7b51b04a4e98f8f59244635cc5
Autor:
Jurre den Haan, Lajos Csinscik, Tom Parker, Ross W. Paterson, Catherine F. Slattery, Alexander Foulkes, Femke H. Bouwman, Frank D. Verbraak, Philip Scheltens, Tunde Peto, Imre Lengyel, Jonathan M. Schott, Sebastian J. Crutch, Timothy J. Shakespeare, Keir X. X. Yong
Publikováno v:
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-9 (2019)
Abstract Background Retinal thickness can be measured non-invasively with optical coherence tomography (OCT) and may offer compelling potential as a biomarker for Alzheimer’s disease (AD). Retinal thinning is hypothesized to be a result of retrogra
Externí odkaz:
https://doaj.org/article/a174b48a2c1e46119b70577fd801cdb9
Autor:
Tara P. Sani, Rebecca L. Bond, Charles R. Marshall, Chris J.D. Hardy, Lucy L. Russell, Katrina M. Moore, Catherine F. Slattery, Ross W. Paterson, Ione O.C. Woollacott, Indra Putra Wendi, Sebastian J. Crutch, Jonathan M. Schott, Jonathan D. Rohrer, Sofia H. Eriksson, Derk-Jan Dijk, Jason D. Warren
Publikováno v:
eNeurologicalSci, Vol 17, Iss , Pp - (2019)
Sleep disruption is a key clinical issue in the dementias but the sleep phenotypes of these diseases remain poorly characterised. Here we addressed this issue in a proof-of-principle study of 67 patients representing major syndromes of frontotemporal
Externí odkaz:
https://doaj.org/article/52b090acccca48a8a16853833b294b68
Autor:
Ross W. Paterson, Catherine F. Slattery, Teresa Poole, Jennifer M. Nicholas, Nadia K. Magdalinou, Jamie Toombs, Miles D. Chapman, Michael P. Lunn, Amanda J. Heslegrave, Martha S Foiani, Philip S. J. Weston, Ashvini Keshavan, Jonathan D. Rohrer, Martin N. Rossor, Jason D. Warren, Catherine J. Mummery, Kaj Blennow, Nick C. Fox, Henrik Zetterberg, Jonathan M. Schott
Publikováno v:
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-11 (2018)
Abstract Background Cerebrospinal fluid (CSF) biomarkers are increasingly being used to support a diagnosis of Alzheimer’s disease (AD). Their clinical utility for differentiating AD from non-AD neurodegenerative dementias, such as dementia with Le
Externí odkaz:
https://doaj.org/article/cd0b740c050b4d6384bd565c2c72b223
Autor:
Anna Drews, Suman De, Patrick Flagmeier, David C. Wirthensohn, Wei-Hsin Chen, Daniel R. Whiten, Margarida Rodrigues, Cécile Vincke, Serge Muyldermans, Ross W. Paterson, Catherine F. Slattery, Nick C. Fox, Jonathan M. Schott, Henrik Zetterberg, Christopher M. Dobson, Sonia Gandhi, David Klenerman
Publikováno v:
Cell Reports, Vol 21, Iss 11, Pp 3310-3316 (2017)
One potential therapeutic strategy for Alzheimer’s disease (AD) is to use antibodies that bind to small soluble protein aggregates to reduce their toxic effects. However, these therapies are rarely tested in human CSF before clinical trials because
Externí odkaz:
https://doaj.org/article/3fb486ca17474719aec0f211bac9ee41
Autor:
Liane S. Canas, Carole H. Sudre, Enrico De Vita, Akin Nihat, Tze How Mok, Catherine F. Slattery, Ross W. Paterson, Alexander J.M. Foulkes, Harpreet Hyare, M. Jorge Cardoso, John Thornton, Jonathan M. Schott, Frederik Barkhof, John Collinge, Sébastien Ourselin, Simon Mead, Marc Modat
Publikováno v:
NeuroImage: Clinical, Vol 24, Iss , Pp - (2019)
Prion diseases are a group of rare neurodegenerative conditions characterised by a high rate of progression and highly heterogeneous phenotypes. Whilst the most common form of prion disease occurs sporadically (sporadic Creutzfeldt–Jakob disease, s
Externí odkaz:
https://doaj.org/article/7a1f7d14910546ba9474019266b13c9d
Autor:
Thomas D. Parker, Catherine F. Slattery, Keir X.X. Yong, Jennifer M. Nicholas, Ross W. Paterson, Alexander J.M. Foulkes, Ian B. Malone, David L. Thomas, David M. Cash, Sebastian J. Crutch, Nick C. Fox, Jonathan M. Schott
Publikováno v:
NeuroImage: Clinical, Vol 21, Iss , Pp - (2019)
The most common presentation of early onset Alzheimer's disease (EOAD – defined as symptom onset
Externí odkaz:
https://doaj.org/article/4096b1db2cce408aaa4e19408aa1c964
Autor:
Ross W. Paterson, Jamie Toombs, Miles D. Chapman, Jennifer M. Nicholas, Amanda J. Heslegrave, Catherine F. Slattery, Alexander J.M. Foulkes, Camilla N. Clark, Christopher A.S. Lane, Philip S.J. Weston, Michael P. Lunn, Nick C. Fox, Henrik Zetterberg, Jonathan M. Schott
Publikováno v:
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 1, Iss 3, Pp 380-384 (2015)
Abstract Introduction Cerebrospinal fluid (CSF) neurodegenerative markers are measured clinically to support a diagnosis of Alzheimer's disease. Several preanalytical factors may alter the CSF concentrations of amyloid β 1–42 (Aβ1–42) in partic
Externí odkaz:
https://doaj.org/article/13480e2160d744c9985b1d432b6a50d2
Autor:
Ivanna M. Pavisic, Nicholas C. Firth, Samuel Parsons, David Martinez Rego, Timothy J. Shakespeare, Keir X. X. Yong, Catherine F. Slattery, Ross W. Paterson, Alexander J. M. Foulkes, Kirsty Macpherson, Amelia M. Carton, Daniel C. Alexander, John Shawe-Taylor, Nick C. Fox, Jonathan M. Schott, Sebastian J. Crutch, Silvia Primativo
Publikováno v:
Frontiers in Neurology, Vol 8 (2017)
Young onset Alzheimer’s disease (YOAD) is defined as symptom onset before the age of 65 years and is particularly associated with phenotypic heterogeneity. Atypical presentations, such as the clinic-radiological visual syndrome posterior cortical a
Externí odkaz:
https://doaj.org/article/618d527a49ed420190f2106b6bf540c1